Antiviral Therapy in Chronic Hepatitis C Virus-related Decompensated Liver Cirrhosis – A Tightrope Walk

摘要: Hepatitis C virus (HCV) is a common cause of liver disease leading to cirrhosis, failure and hepatocellular carcinoma (HCC). Worldwide, HCV-related end-stage the most indication for transplantation. It estimated that 170 million people are infected worldwide. Prevalence HCV infection reported be 12% in some centers Middle East 32.3 patients found South Asia East.[1] One third likely develop cirrhosis complications significant morbidity, mortality need Use pegylated interferon ribavirin standard care treatment acute chronic without decompensation.[2,3] Decompensated with undergo Patients who transplantation related decompensated or HCC have recurrence universally. Currently published Asian Pacific Association Study Liver (APASL) guidelines 2007[2] recommend due should not treated current therapy general setting referred The more recent American (AASLD) guidelines[3] Interferon-based may started low dose escalating manner but administering this needs an experienced clinician vigilant monitoring, any adverse event, preferably already listed Growth factors can used associated anemia leucopenia improve quality life limit antiviral reduction.